Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Abaloparatide improves BMD in postmenopausal women with osteoporosis and T2D

Key clinical point: In postmenopausal women with osteoporosis and type 2 diabetes (T2D), abaloparatide treatment is associated with significant improvements in bone mineral density (BMD) and trabecular bone score (TBS) compared with placebo.

Major finding: From baseline to 18 months, the least-squares mean difference in change in BMD at total hip, femoral neck, and lumbar spine between the abaloparatide and placebo groups was 3.3%, 2.8%, and 7.6%, respectively (P less than .001 at all 3 sites). Lumbar spine TBS significantly improved in the abaloparatide vs. placebo group (mean percent change, 3.72% vs. −0.56%; P less than .001).

Study details: Post hoc analysis of the ACTIVE trial included 198 postmenopausal women with osteoporosis and T2D.Disclosures: This study was funded by Radius Health, Inc. Three of the authors are employees of and own stock in Radius Health, Inc. and one is a consultant and other is a board member, consultant for and own stock in Radius Health, Inc.

Citation:

Dhaliwal R et al. JBMR Plus. 2020 Feb 27. doi: 10.1002/jbm4.10346.